Bret Stephens’ Pharmapologetics
Now, when the demand for both innovation and access is high, it’s time to think outside the box and reevaluate the relationship between pharmaceutical drugs and the patent system. Perhaps a prize system is in order, or maybe a formal guarantee from firms receiving BARDA grants that the drugs will not be patented.Featured Publications
Scams Were Already Awful. Then They Got AI.
Data First: Tracking Medical and Geriatric Parole Outcomes in Tennessee
Understanding Federal Law Enforcement in the United States
Don’t Let the “War on Fraud” Become Another DOGE
Statement responding to the Trump administration’s new National Cybersecurity Strategy
Statement on new executive order to combat fraud and scams
Low-Energy Fridays: Conflict in Iran raises energy prices, but how should that inform policy?
Amid war in Iran, the White House misunderstands how political risk insurance works








